loading page

MicroRNA expression profile predicts prognosis of pediatric adrenocortical tumors
  • +14
  • Luciana Veronez,
  • Paola Fedatto,
  • Carolina Corrêa,
  • Régia Lira,
  • Mirella Baroni,
  • Keteryne Silva,
  • Paula Santos,
  • David Antonio,
  • Rosane Queiroz,
  • Sonir Antonini,
  • Silvio Tucci Jr,
  • Luciano Neder,
  • Jose Yunes,
  • Silvia Brandalise,
  • Rodrigo Panepucci,
  • Luiz Gonzaga Tone,
  • Carlos Scrideli
Luciana Veronez
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Paola Fedatto
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Carolina Corrêa
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Régia Lira
Faculty of Medicine of Ribeirão Preto, University of São Paulo
Author Profile
Mirella Baroni
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Keteryne Silva
Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto
Author Profile
Paula Santos
University of Sao Paulo Faculty of Philosophy Letters and Human Sciences
Author Profile
David Antonio
Seven Bridges Biotech Consulting
Author Profile
Rosane Queiroz
Faculdade de Medicina de Ribeirão Preto, Universidade de Sao Paulo
Author Profile
Sonir Antonini
School of Medicine of Ribeirão Preto
Author Profile
Silvio Tucci Jr
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Luciano Neder
Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil.
Author Profile
Jose Yunes
Centro Infantil Boldrini
Author Profile
Silvia Brandalise
Centro Infantil Boldrini
Author Profile
Rodrigo Panepucci
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Luiz Gonzaga Tone
Universidade de Sao Paulo Faculdade de Medicina de Ribeirao Preto
Author Profile
Carlos Scrideli
Universidade de São Paulo (USP)
Author Profile

Abstract

Pediatric adrenocortical tumors (ACT) are rare aggressive neoplasms with heterogeneous prognosis. Despite extensive efforts, identifying reliable prognostic factors for pediatric patients with ACT remains a challenge. MicroRNA (miRNA) signatures have been associated with cancer diagnosis, treatment response, and prognosis of several types of cancer. However, the role of miRNAs has been poorly explored in pediatric ACT. In this study, we performed miRNA microarray profiling on a cohort of 37 pediatric ACT and nine non-neoplastic adrenal (NNA) samples and evaluated the prognostic significance of abnormally expressed miRNAs using Kaplan-Meier plots, log-rank test and Cox regression analysis. We identified a total of 98 abnormally expressed miRNAs, which expression profile discriminated ACT from NNAs. Among the 98 deregulated miRNAs, 17 presented significant associations with patients’ survival. In addition, higher expression levels of hsa-miR-630, -139-3p, -125a-3p, -574-5p, -596, -564, -1321, and -423-5p and lower expression levels of hsa-miR-377-3p, -126-3p, -410, -136-3p, -29b-3p, -29a-3p, -337-5p, -143-3p, and 140-5p were significantly associated with poor prognosis, tumor relapse, and/or death. Importantly, the expression profile of these 17 miRNAs stratified patients into two groups of ACTs with different clinical outcomes. Although some individual miRNAs exhibit potential prognostic values in ACTs, only the 17 miRNA-based expression clustering was considered an independent prognostic factor for five-year event-free survival (EFS) compared to other clinicopathological features. In conclusion, our study reports for the first time associations between miRNA profiles and childhood ACT prognosis, providing evidence that miRNAs could be useful biomarkers to discriminate patients with favorable and unfavorable clinical outcomes.
04 Oct 2021Submitted to Pediatric Blood & Cancer
04 Oct 2021Submission Checks Completed
04 Oct 2021Assigned to Editor
16 Oct 2021Reviewer(s) Assigned
28 Oct 2021Review(s) Completed, Editorial Evaluation Pending
01 Nov 2021Editorial Decision: Revise Minor
01 Dec 20211st Revision Received
01 Dec 2021Submission Checks Completed
01 Dec 2021Assigned to Editor
08 Dec 2021Reviewer(s) Assigned
08 Dec 2021Review(s) Completed, Editorial Evaluation Pending
13 Dec 2021Editorial Decision: Accept
31 Dec 2021Published in Pediatric Blood & Cancer. 10.1002/pbc.29553